| scholarly article | Q13442814 |
| P2093 | author name string | Sanjay Bhanot | |
| Xing Xian Yu | |||
| Brett P Monia | |||
| Sanjay K Pandey | |||
| Susan F Murray | |||
| Dingjiu Bao | |||
| Susan Kelly | |||
| Robert McKay | |||
| Songyuan Chen | |||
| Sheri L Booten | |||
| Xiu-Zhen Song | |||
| P2860 | cites work | Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes | Q44007180 |
| Sterol regulatory element binding protein-1c expression and action in rat muscles: insulin-like effects on the control of glycolytic and lipogenic enzymes and UCP3 gene expression | Q44007196 | ||
| Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. | Q44477314 | ||
| An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis | Q45270105 | ||
| Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter | Q46133867 | ||
| Effects of high fat-feeding to rats on the interrelationship of body weight, plasma insulin, and fatty acyl-coenzyme A esters in liver and skeletal muscle | Q47412626 | ||
| Rates of mitochondrial and peroxisomal beta-oxidation of palmitate change during postnatal development and food deprivation in liver, kidney and heart of pigs | Q48739277 | ||
| Skeletal muscle triglyceride levels are inversely related to insulin action. | Q51575343 | ||
| High-fat hypercaloric diet induces obesity, glucose intolerance and hyperlipidemia in normal adult male Wistar rat. | Q51582379 | ||
| High dietary fat promotes syndrome X in nonobese rats | Q73609365 | ||
| Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding | Q73842112 | ||
| Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members | Q24291503 | ||
| Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis | Q24645996 | ||
| Lipopenia and skin barrier abnormalities in DGAT2-deficient mice | Q28585990 | ||
| Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase | Q28609414 | ||
| The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. | Q31806021 | ||
| Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat | Q33901239 | ||
| Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance | Q34399523 | ||
| Insulin resistance in type 2 diabetes: role of fatty acids | Q34580981 | ||
| Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. | Q34790962 | ||
| Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes | Q34835012 | ||
| Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia | Q35210038 | ||
| Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. | Q38299766 | ||
| Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. | Q42088836 | ||
| Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. | Q42997321 | ||
| Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol | Q43646231 | ||
| Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression | Q43748930 | ||
| Reduced body fat and increased hepatic lipid synthesis in mice bearing interleukin-6-secreting tumor | Q43762936 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| steatosis | Q1365091 | ||
| hyperlipidemia | Q1079120 | ||
| P304 | page(s) | 362-371 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice | |
| P478 | volume | 42 |
| Q44931121 | A lipidomic analysis of nonalcoholic fatty liver disease. |
| Q90719687 | A novel role for DGATs in cancer |
| Q51391222 | Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice. |
| Q53259889 | An editor's look-back. |
| Q38850010 | Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia |
| Q60921114 | Apple Pomace Consumption Favorably Alters Hepatic Lipid Metabolism in Young Female Sprague-Dawley Rats Fed a Western Diet |
| Q52571243 | Colocalization of SCD1 and DGAT2: implying preference for endogenous monounsaturated fatty acids in triglyceride synthesis. |
| Q37485124 | Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis |
| Q38588541 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies |
| Q37860216 | Cytochrome P450 2E1 and hyperglycemia-induced liver injury |
| Q43184237 | DGAT1, DGAT2 and PDAT expression in seeds and other tissues of epoxy and hydroxy fatty acid accumulating plants |
| Q38317230 | Delivery of RNAi reagents in murine models of obesity and diabetes |
| Q36042028 | Detection of differentially expressed candidate genes for a fatty liver QTL on mouse chromosome 12. |
| Q51116597 | Dgat1 and Dgat2 regulate enterocyte triacylglycerol distribution and alter proteins associated with cytoplasmic lipid droplets in response to dietary fat. |
| Q28572478 | Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis |
| Q39322543 | Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de novo synthesized fatty acids in HepG2 cells |
| Q50952043 | Dietary Omega-3 Fatty Acids Prevented Adipocyte Hypertrophy by Downregulating DGAT-2 and FABP-4 in a Sex-Dependent Fashion. |
| Q28547562 | Dietary Tributyrin Supplementation Attenuates Insulin Resistance and Abnormal Lipid Metabolism in Suckling Piglets with Intrauterine Growth Retardation |
| Q58110770 | Differential capability of metabolic substrates to promote hepatocellular lipid accumulation |
| Q46577273 | Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers |
| Q38050214 | Dissociating fatty liver and diabetes |
| Q37400771 | Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene |
| Q55092943 | Dual extraction of mRNA and lipids from a single biological sample. |
| Q37230403 | Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers |
| Q80670436 | Effects of cysteine-containing compounds on biosynthesis of triacylglycerol and cholesterol and anti-oxidative protection in liver from mice consuming a high-fat diet |
| Q35432791 | Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug |
| Q36152978 | Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia. |
| Q34125393 | Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver |
| Q27938569 | Functional and topological analysis of yeast acyl-CoA:diacylglycerol acyltransferase 2, an endoplasmic reticulum enzyme essential for triacylglycerol biosynthesis |
| Q35884548 | Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies |
| Q34646183 | Genetic determinants of hepatic steatosis in man. |
| Q26865248 | Genetically modified mouse models for the study of nonalcoholic fatty liver disease |
| Q33869725 | Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity |
| Q80407703 | Good fat/bad fat |
| Q35809069 | Hepatic Steatosis as a Marker of Metabolic Dysfunction. |
| Q46706731 | Hepatic and adipose tissue depot-specific changes in lipid metabolism in Late-onset Obese (LOB) rats |
| Q37296476 | Hepatic fatty acid trafficking: multiple forks in the road |
| Q37777696 | Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites |
| Q34188050 | Hepatic long-chain acyl-CoA synthetase 5 mediates fatty acid channeling between anabolic and catabolic pathways |
| Q37321860 | Hepatic triacylglycerol accumulation and insulin resistance. |
| Q35604983 | Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis |
| Q91966496 | Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice |
| Q86932298 | Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: potential role of PPARγ |
| Q34287889 | High-content assays for evaluating cellular and hepatic diacylglycerol acyltransferase activity |
| Q38832781 | Identification of DGAT2 Inhibitors Using Mass Spectrometry |
| Q28281865 | Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity |
| Q24547511 | Improved targeting of miRNA with antisense oligonucleotides |
| Q39541130 | Increased expression of enzymes of triglyceride synthesis is essential for the development of hepatic steatosis |
| Q30453231 | Inflammation in nonalcoholic steatohepatitis |
| Q53555710 | Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. |
| Q37044780 | Inhibition of microRNA with antisense oligonucleotides |
| Q37658846 | Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents |
| Q92180471 | Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits |
| Q36302747 | Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying |
| Q34187979 | Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease |
| Q34427355 | Lactase persistence and lipid pathway selection in the Maasai |
| Q38080471 | Latest research and development trends in non-insulin anti-diabetics |
| Q39253589 | Lipid droplets and liver disease: from basic biology to clinical implications. |
| Q33843550 | Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms |
| Q35839709 | Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients |
| Q35217044 | Liver-specific loss of lipin-1-mediated phosphatidic acid phosphatase activity does not mitigate intrahepatic TG accumulation in mice |
| Q90542982 | Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming |
| Q50053108 | Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. |
| Q90031078 | Metabolic Targets in Nonalcoholic Fatty Liver Disease |
| Q24629354 | MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism |
| Q36452544 | Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome |
| Q33755566 | Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH) |
| Q33585604 | Molecular mechanisms involved in hepatic steatosis and insulin resistance |
| Q27007515 | Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH) |
| Q37350168 | Niacin: an old drug rejuvenated |
| Q42806308 | Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation |
| Q40729988 | Nonalcoholic fatty liver disease: from lipid profile to treatment |
| Q37229854 | Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis |
| Q34559896 | Novel acyl-coenzyme A:monoacylglycerol acyltransferase plays an important role in hepatic triacylglycerol secretion |
| Q96585240 | Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial |
| Q36617551 | Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications |
| Q34901544 | Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice |
| Q37504529 | Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect |
| Q35823390 | Phospholipid transfer activity of microsomal triglyceride transfer protein produces apolipoprotein B and reduces hepatosteatosis while maintaining low plasma lipids in mice |
| Q38195808 | Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition |
| Q41785858 | Probing the role of stearoyl-CoA desaturase-1 in hepatic insulin resistance |
| Q64964830 | Pterostilbene Reduces Liver Steatosis and Modifies Hepatic Fatty Acid Profile in Obese Rats. |
| Q38294486 | Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression |
| Q38290376 | Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice |
| Q38303815 | Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice |
| Q28507784 | Regulation of hepatic lipogenesis by the transcription factor XBP1 |
| Q36649458 | Regulation of triglyceride metabolism. I. Eukaryotic neutral lipid synthesis: "Many ways to skin ACAT or a DGAT". |
| Q41888381 | Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing |
| Q28594538 | Resistance to diet-induced obesity and associated metabolic perturbations in haploinsufficient monocarboxylate transporter 1 mice |
| Q42033681 | Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. |
| Q34628676 | Sequential regulation of diacylglycerol acyltransferase 2 expression by CAAT/enhancer-binding protein beta (C/EBPbeta) and C/EBPalpha during adipogenesis |
| Q39975300 | Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia |
| Q64949842 | Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile. |
| Q34989773 | Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids |
| Q34485836 | Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis |
| Q59049645 | Targeting Hepatic Glycerolipid Synthesis and Turnover to Treat Fatty Liver Disease |
| Q93249947 | Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis |
| Q47351487 | Targeting energy expenditure via fuel switching and beyond |
| Q96609644 | The Role of Bone Morphogenetic Protein Signaling in Non-Alcoholic Fatty Liver Disease |
| Q36364289 | The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease. |
| Q37583530 | The endoplasmic reticulum coat protein II transport machinery coordinates cellular lipid secretion and cholesterol biosynthesis |
| Q37264190 | The genetics of neutral lipid biosynthesis: an evolutionary perspective |
| Q35811523 | The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes |
| Q35090215 | The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. |
| Q35958448 | The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2 |
| Q34817393 | Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis |
| Q43582639 | Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease |
| Q34401755 | Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats |
| Q38222366 | Therapeutic strategies for metabolic diseases: Small-molecule diacylglycerol acyltransferase (DGAT) inhibitors |
| Q36772888 | Thermogenic and metabolic antiobesity drugs: rationale and opportunities |
| Q35743140 | Treatment of rats with Jiangzhi Capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2. |
| Q43051400 | Triazolo compounds useful as diacylglycerol acyltransferase1 inhibitor - WO2009126624. |
| Q39516919 | Trivalent chromium alleviates oleic acid induced steatosis in SMMC-7721 cells by decreasing fatty acid uptake and triglyceride synthesis |
| Q36520423 | Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis |
| Q50556171 | Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. |
| Q28542460 | Whole genome transcript profiling of drug induced steatosis in rats reveals a gene signature predictive of outcome |
Search more.